Leussink Verena I, Hartung Hans-Peter, Kieseier Bernd C, Stettner Mark
Department of Neurology, Medical Faculty, Research Group for Clinical and Experimental Neuroimmunology, Heinrich-Heine-University, Düsseldorf, Germany.
Department of Neurology, Heinrich-Heine-University, Moorenstr. 5, 40225 Düsseldorf, Germany.
Ther Adv Neurol Disord. 2016 Jul;9(4):336-43. doi: 10.1177/1756285616641583. Epub 2016 Apr 6.
Intravenous immunoglobulins represent an established therapy for the treatment of chronic immune-mediated neuropathies, specifically chronic inflammatory demyelinating polyradiculoneuropathies (CIDPs) as well as multifocal motor neuropathies (MMNs). For the treatment of antibody deficiency syndromes, subcutaneous immunoglobulins (SCIgs) have represented a mainstay for decades. An emerging body of evidence suggests that SCIg might also exhibit clinical efficacy in CIDP and MMN. This article reviews the current evidence for clinical effectiveness, as well as safety of SCIg for the treatment of immune-mediated neuropathies, and addresses remaining open questions in this context. We conclude that despite the need for controlled long-term studies to demonstrate long-term efficacy of SCIg in immune-mediated neuropathies, SCIg may already represent a potential therapeutic alternative for selected patients.
静脉注射免疫球蛋白是治疗慢性免疫介导性神经病的既定疗法，特别是慢性炎症性脱髓鞘性多发性神经根神经病（CIDP）以及多灶性运动神经病（MMN）。几十年来，皮下注射免疫球蛋白（SCIg）一直是治疗抗体缺乏综合征的主要手段。越来越多的证据表明，SCIg在CIDP和MMN中可能也具有临床疗效。本文综述了SCIg治疗免疫介导性神经病的临床有效性及安全性的现有证据，并探讨了这方面尚存的未决问题。我们得出结论，尽管需要进行对照长期研究来证明SCIg在免疫介导性神经病中的长期疗效，但对于部分患者而言，SCIg可能已成为一种潜在的治疗选择。
